[TABLE OF CONTENTS]

1 INTRODUCTION OF GLOBAL ERECTILE DYSFUNCTION MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY: ERECTILE DYSFUNCTION MARKET

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS

4 GLOBAL ERECTILE DYSFUNCTION MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE

5 GLOBAL ERECTILE DYSFUNCTION MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 VIAGRA
5.3 CIALIS
5.4 ZYDENA
5.5 LEVITRA
5.6 STENDRA
5.7 OTHERS

6 GLOBAL ERECTILE DYSFUNCTION MARKET, BY GEOGRAPHY
6.1 OVERVIEW

6.2 NORTH AMERICA

6.2.1 NORTH AMERICA MARKET SNAPSHOT
6.2.2 U.S.
6.2.3 CANADA
6.2.4 MEXICO

6.3 EUROPE

6.3.1 EUROPE MARKET SNAPSHOT
6.3.2 WESTERN EUROPE
6.3.2.1 THE UK
6.3.2.2 GERMANY
6.3.2.3 FRANCE
6.3.2.4 ITALY
6.3.2.5 SPAIN
6.3.2.6 REST OF WESTERN EUROPE
6.3.3 EASTERN EUROPE
6.3.3.1 POLAND
6.3.3.2 RUSSIA
6.3.3.3 REST OF EASTERN EUROPE

6.4 ASIA PACIFIC

6.4.1 ASIA PACIFIC MARKET SNAPSHOT
6.4.2 CHINA
6.4.3 JAPAN
6.4.4 INDIA
6.4.5 AUSTRALIA & NEW ZEALAND
6.4.6 ASEAN
6.4.7 REST OF ASIA PACIFIC

6.5 MIDDLE EAST & AFRICA

6.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
6.5.2 UAE
6.5.3 SAUDI ARABIA
6.5.4 SOUTH AFRICA
6.5.5 REST OF MEA

6.6 SOUTH AMERICA

6.6.1 SOUTH AMERICA MARKET SNAPSHOT
6.6.2 BRAZIL
6.6.3 ARGENTINA
6.6.4 REST OF SOUTH AMERICA

7 GLOBAL ERECTILE DYSFUNCTION MARKET COMPETITIVE LANDSCAPE
7.1 OVERVIEW
7.2 COMPANY MARKET RANKING
7.3 KEY DEVELOPMENT STRATEGIES
7.4 COMPETITIVE DASHBOARD
7.5 PRODUCT MAPPING
7.6 TOP PLAYER POSITIONING, 2022
7.7 COMPETITIVE HEATMAP
7.8 TOP WINNING STRATEGIES

8 COMPANY PROFILES

8.1 PFIZER INC
8.1.1 OVERVIEW
8.1.2 FINANCIAL PERFORMANCE
8.1.3 PRODUCT OUTLOOK
8.1.4 KEY DEVELOPMENTS
8.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.2 ELI LILLY AND COMPANY
8.2.1 OVERVIEW
8.2.2 FINANCIAL PERFORMANCE
8.2.3 PRODUCT OUTLOOK
8.2.4 KEY DEVELOPMENTS
8.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.3 BAYER AG
8.3.1 OVERVIEW
8.3.2 FINANCIAL PERFORMANCE
8.3.3 PRODUCT OUTLOOK
8.3.4 KEY DEVELOPMENTS
8.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.4 VIVUS INC
8.4.1 OVERVIEW
8.4.2 FINANCIAL PERFORMANCE
8.4.3 PRODUCT OUTLOOK
8.4.4 KEY DEVELOPMENTS
8.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.5 DONG-A ST CO. LTD
8.5.1 OVERVIEW
8.5.2 FINANCIAL PERFORMANCE
8.5.3 PRODUCT OUTLOOK
8.5.4 KEY DEVELOPMENTS
8.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.6 MEDA PHARMACEUTICALS INC
8.6.1 OVERVIEW
8.6.2 FINANCIAL PERFORMANCE
8.6.3 PRODUCT OUTLOOK
8.6.4 KEY DEVELOPMENTS
8.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.7 S.K. CHEMICALS CO. LTD
8.7.1 OVERVIEW
8.7.2 FINANCIAL PERFORMANCE
8.7.3 PRODUCT OUTLOOK
8.7.4 KEY DEVELOPMENTS
8.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
8.8.1 OVERVIEW
8.8.2 FINANCIAL PERFORMANCE
8.8.3 PRODUCT OUTLOOK
8.8.4 KEY DEVELOPMENTS
8.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.9 ENDO INTERNATIONAL PLC
8.9.1 OVERVIEW
8.9.2 FINANCIAL PERFORMANCE
8.9.3 PRODUCT OUTLOOK
8.9.4 KEY DEVELOPMENTS
8.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.10 FUTURA MEDICAL PLC
8.10.1 OVERVIEW
8.10.2 FINANCIAL PERFORMANCE
8.10.3 PRODUCT OUTLOOK
8.10.4 KEY DEVELOPMENTS
8.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.11 APRICUS BIOSCIENCES INC
8.11.1 OVERVIEW
8.11.2 FINANCIAL PERFORMANCE
8.11.3 PRODUCT OUTLOOK
8.11.4 KEY DEVELOPMENTS
8.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.12 MEDTRONIC PLC
8.12.1 OVERVIEW
8.12.2 FINANCIAL PERFORMANCE
8.12.3 PRODUCT OUTLOOK
8.12.4 KEY DEVELOPMENTS
8.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.13 COLOPLAST CORP
8.13.1 OVERVIEW
8.13.2 FINANCIAL PERFORMANCE
8.13.3 PRODUCT OUTLOOK
8.13.4 KEY DEVELOPMENTS
8.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.14 BOSTON SCIENTIFIC CORPORATION
8.14.1 OVERVIEW
8.14.2 FINANCIAL PERFORMANCE
8.14.3 PRODUCT OUTLOOK
8.14.4 KEY DEVELOPMENTS
8.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.15 ZEPHYR SURGICAL IMPLANTS
8.15.1 OVERVIEW
8.15.2 FINANCIAL PERFORMANCE
8.15.3 PRODUCT OUTLOOK
8.15.4 KEY DEVELOPMENTS
8.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.16 UROLOGIX
8.16.1 OVERVIEW
8.16.2 FINANCIAL PERFORMANCE
8.16.3 PRODUCT OUTLOOK
8.16.4 KEY DEVELOPMENTS
8.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.17 AMERICAN MEDICAL SYSTEMS
8.17.1 OVERVIEW
8.17.2 FINANCIAL PERFORMANCE
8.17.3 PRODUCT OUTLOOK
8.17.4 KEY DEVELOPMENTS
8.17.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.18 AUGUSTA MEDICAL SYSTEMS
8.18.1 OVERVIEW
8.18.2 FINANCIAL PERFORMANCE
8.18.3 PRODUCT OUTLOOK
8.18.4 KEY DEVELOPMENTS
8.18.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.19 POS-T-VAC MEDICAL
8.19.1 OVERVIEW
8.19.2 FINANCIAL PERFORMANCE
8.19.3 PRODUCT OUTLOOK
8.19.4 KEY DEVELOPMENTS
8.19.5 KEY STRATEGIC MOVES AND DEVELOPMENTS